Horizon Scanning in Oncology: Decision Support Documents No. 25, 26 & 28 online
Romidepsin (Istodax®) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) after prior systemic therapy New!
Brentuximab (Adcetris®) for the treatment of relapsed Hodgkin’s lymphoma (HL) or relapsed systemic anaplastic large cell lymphoma (sALCL) New!
Lenalidomide (Revlimid®) for the treatment of low /intermediate-1 risk myelodysplastic syndrome with chromosome 5q deletion New!
Axitinib (AG013736, Inlyta®) for the second-line treatment of metastatic renal cell carcinoma (mRCC)
Erlotinib (Tarceva®) for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations
Everolimus (Afinitor®) for the treatment of unresectable or metastatic neuroendocrine tumours of pancreatic origin
Abiraterone acetate (ZytigaTM) as 2nd-line therapy for the treatment of metastatic castration-resistant prostate cancer after docetaxel therapy
Rituximab (Rituxan®/MabThera®) for the first- and second-line treatment of chronic lymphocytic leukaemia – 1st Update 2011
Panitumumab (Vectibix®) as 1st-line combination therapy for the treatment of WT KRAS metastatic colorectal cancer
Gefitinib (Iressa®) for the 1st-line treatment of non-small cell lung cancer – 1st Update 2011
Second-line chemotherapy with cabazitaxel (Jevtana®) for the treatment of castration-resistant metastatic prostate cancer
Dasatinib (Sprycel®) for the 1st-line treatment of Philadelphia-chromosome positive chronic myeloid leukemia in the chronic phase
Ipilimumab for pre-treated patients with advanced/ metastatic melanoma
Nilotinib (Tasigna®) for the 1st-line treatment of Philadelphia chromosome positive chronic myeloid leukemia in the chronic phase
Lapatinib ditosylate (Tyverb/Tykerb®) as first-line therapy for the treatment of advanced/metastatic breast cancer
Bendamustine (Ribomustin®/Treanda®/ Levact®) for indolent non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukaemia (CLL) and multiple myeloma
Panitumumab (Vectibix®) for the first-line treatment of metastatic colorectal cancer
Trastuzumab (Herceptin®) in addition to standard chemotherapy as first-line therapy for advanced gastric cancer
Azacitidine (Vidaza®) for the treatment of myelodysplastic syndromes
Cetuximab (Erbitux®) in EGFR-expressing Non-Small Cell Lung Cancer
Everolimus (Afinitor®) for the treatment of advanced/metastatic kidney cancer
Rituximab (Rituxan®/MabThera®) for the first- and second-line treatment of chronic lymphocytic leukaemia
Ibritumomab tiuxetan (Zevalin®) as consolidation therapy after first remission in patients with follicular lymphoma